From: Changes in therapy and survival of metastatic renal cell carcinoma in Estonia
Median survival in months (95% CI) | ||
---|---|---|
Total | 13.7 (11.3–16.2) | |
Age group | ||
15–59 | 11.1 (8.0–17.7) | p = 0.667 |
60–69 | 14.6 (11.7–20.6) | |
70+ | 13.1 (9.2–19.0) | |
Treatment started | ||
2004–2007 | 9.7 (8.1–14.8) | p = 0.087 |
2008–2012 | 15.4 (12.2–19.8) | |
Sex | ||
Male | 11.9 (9.1–15.4) | p = 0.104 |
Female | 18.3 (12.1–22.9) | |
Nephrectomy | ||
Done | 16.0 (13.1–19.5) | p < 0.001 |
Not done | 7.0 (3.8–8.7) | |
Histology | ||
Clear Cell | 16.1 (12.9–19.5) | p = 0.002 |
Non-Clear Cell | 7.0 (4.7–9.7) | |
Prognostic group (only 2008–2012) | ||
Favorable | 28.4 (22.2–55.7) | p < 0.001 |
Intermediate | 13.2 (10.4–16.9) | |
Poor | 2.4 (1.1–8.5) | |
Unknown | 15.2 (5.5–21.0) |